Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRO-IMMUN
DRKS00004858Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Mar 2014
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aldesleukin in systemic lupus erythematosus (SLE), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoints: Safety and tolerability of Aldesleukin, Efficacy of Aldesleukin in systemic lupus erythematosus and 1 more. Started Mar 2014; status: completed.
02
Drugs
aldesleukin
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on DRKS00004858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00004858.